A local patient has become the first in the world to receive a new form of cell therapy being trialled at The Christie hospital in Manchester. The treatment, called ZI-MA4-1, was given to a 58-year-old woman from Chadderton who was diagnosed with ovarian cancer in 2020.
What the treatment does
The experimental therapy combines two immune approaches. It harnesses natural killer (NK) cells — specialised immune cells that destroy abnormal cells — and engineers their T-cell receptors to recognise tumours that produce a protein known as Mage-A4. Mage-A4 is present in several cancer types, which is why the trial will recruit patients with a range of tumours.
Trial scope and local connection
The trial is being led by The Christie, with an additional site at the Royal Marsden in London. It will include people with:
- ovarian cancer
- lung cancer
- sarcomas
- head and neck cancers
Unlike personalised therapies derived from a patient’s own cells, ZI-MA4-1 is produced from donor immune cells and stored in advance. That "off-the-shelf" approach means hundreds of doses can be manufactured from a single batch, which could make advanced cell treatments accessible to more patients more quickly and at lower cost if the trial is successful.
"I appreciate the smallest of things that we take for granted,"
The patient, a former civil service manager, said she decided early to take part in the trial despite feeling it was "a little bit scary" to be the first recipient. She was originally diagnosed at stage 3C, with cancer spread into the peritoneum, and has since had surgery and several courses of chemotherapy.
Why this matters locally
For Oldham and surrounding areas, the trial represents both hope for people with advanced cancers and a reminder of the importance of regional specialist centres. The Christie is already a major centre for cancer care and research in the north west, and participating in early-stage studies helps bring cutting-edge options within reach of local patients.
| Feature | Detail |
|---|---|
| Therapy name | ZI-MA4-1 |
| Target protein | Mage-A4 |
| Trial sites | The Christie (Manchester), Royal Marsden (London) |
| Cancer types included | Ovarian, lung, sarcoma, head and neck |
Patients who take part in early-phase trials typically do so when standard treatments have limited benefit. Such studies are primarily focused on safety and establishing appropriate dosing, although they can also provide vital information on whether a treatment might be effective.
For people in Oldham considering trial participation, discussion with their oncologist is essential to weigh potential risks and benefits. Local specialists at The Christie and community clinicians will be able to advise whether an individual is eligible and how to enrol.
This first-ever administration of ZI-MA4-1 marks an important step in the UK’s contribution to cell therapy research and is a moment of particular significance for the patient and her community in Chadderton.
